1.Does contralateral knee range of motion predict postoperative knee range of motion after total knee arthroplasty?
Robert R. BURNHAM JR ; Samantha E. BIALEK ; Amy WOZNIAK ; Nicholas M. BROWN
The Journal of Korean Knee Society 2020;32(2):e26-
Purpose:
The aim of this study was to determine if contralateral knee range of motion is associated with postoperative range of motion in the operative knee after total knee arthroplasty.
Methods:
Contralateral (nonoperative) knee range of motion was compared to postoperative knee range of motion after total knee arthroplasty using linear regression models in 59 patients who had undergone primary total knee arthroplasty with a minimum of 4 months postoperative follow-up data (range 4–13 months).
Results:
A strong linear relationship was observed between contralateral knee ranges of motion of 115° or greater and postoperative knee ranges of motion after total knee arthroplasty (slope 0.93, 95% CI 0.58–1.29, P < 0.0001), with a mean difference of −7.44° (95% CI −10.3 to −4.63, P < 0.0001). However, there was no association between contralateral knee range of motion and postoperative knee range of motion when contralateral knee range of motion was less than 115°.
Conclusion
Contralateral knee range of motion of 115° or greater correlates linearly with postoperative range of motion after total knee arthroplasty, and thus may be predictive in such cases.
2.Comparison of transarterial n-BCA and Onyx embolization of brain arteriovenous malformations: A single-center 18-year retrospective analysis
Faraz BEHZADI ; Daniel M HEIFERMAN ; Amy WOZNIAK ; Benjamin AFRICK ; Matthew BALLARD ; Joshua CHAZARO ; Brandon ZSIGRAY ; Matthew REYNOLDS ; Douglas E ANDERSON ; Joseph C SERRONE
Journal of Cerebrovascular and Endovascular Neurosurgery 2022;24(2):144-153
Objective:
Brain arteriovenous malformations (AVM) are commonly treated with endovascular embolization. Due to the rapid evolution of endovascular technology and lack of consistent practice guidelines regarding AVM embolization, further study of AVM embolization outcomes is warranted.
Methods:
We conducted a retrospective review of AVMs embolized at a single center from 2002-2019. Patient demographics, AVM characteristics, intention of embolization, and angiographic and clinical outcome after embolization were recorded. We compared the embolization results of those treated with n-butyl cyanoacrylate (n-BCA) and Onyx.
Results:
Over an 18-year period at our institution, 30 (33%) of 92 AVMs were treated with embolization. n-BCA was used in 12 cases and Onyx in 18 cases. Eighty-seven pedicles were embolized over 47 embolization sessions. Fifty percent of AVMs treated with n-BCA underwent more than one embolization session compared to 22% when Onyx was used. The median total percent volume reduction in the n-BCA AVMs was 52% compared to 51% in Onyx AVMs. There were 2 periprocedural complications in the n-BCA cohort and none in the Onyx cohort.
Conclusions
In this small retrospective series, Onyx and n-BCA achieved similar occlusion results, although n-BCA required more sessions and pedicles embolized to do so.